Maria Dorrucci

Dr. Maria Dorrucci


Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 August 2009 in AIDS
Verified
Journal Article
Closed access
BMBenoît Marin
Benoît Marin
RTRodolphe Thiébaut
Rodolphe Thiébaut
HBHeiner C Bucher
Heiner C Bucher
VRVirginie Rondeau
Virginie Rondeau
DCDominique Costagliola
Dominique Costagliola
GCGeneviève Chêne
Geneviève Chêne
Objective: To assess whether immunodeficiency is associated with the most frequent non-AIDS-defining causes of death in the era of combination antiretroviral therapy (cART). Design: Observational multicentre cohorts. Methods: Twenty-three cohorts of adults with estimated dates of human immunodeficiency virus (HIV) seroconversion were considered. Patients were seroconverters followed within the cART era. Measurements were latest CD4, nadir CD4 and time spent with CD4 cell count less than 350 cells/μl. Outcomes were specific causes of death using a standardized classification. Results: Among 9858 patients (71 230 person-years follow-up), 597 died, 333 (55.7%) from non-AIDS-defining causes. Non-AIDS-defining infection, liver disease, non-AIDS-defining malignancy and cardiovascular disease accounted for 53% of non-AIDS deaths. For each 100 cells/μl increment in the latest CD4 cell count, we found a 64% (95% confidence interval 58–69%) reduction in risk of death from AIDS-defining causes and significant reductions in death from non-AIDS infections (32, 18–44%), end-stage liver disease (33, 18–46%) and non-AIDS malignancies (34, 21–45%). Non-AIDS-defining causes of death were also associated with nadir CD4 while being cART-naive or duration of exposure to immunosuppression. No relationship between risk of death from cardiovascular disease and CD4 cell count was found though there was a raised risk associated with elevated HIV RNA. Conclusion: In the cART era, the most frequent non-AIDS-defining causes of death are associated with immunodeficiency, only cardiovascular disease was associated with high viral replication. Avoiding profound and mild immunodeficiency, through earlier initiation of cART, may impact on morbidity and mortality of HIV-infected patients.

27 February 2008 in Annals of Neurology
Verified
Journal Article
Closed access
PDF file
KBKrishnan Bhaskaran
Krishnan Bhaskaran
CMCristina Mussini
Cristina Mussini
AAAndrea Antinori
Andrea Antinori
AWAnn Sarah Walker
Ann Sarah Walker
MDMaria Dorrucci
Maria Dorrucci
CCCASCADE Collaboration
CASCADE Collaboration

22 January 2014 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
FEFrederik N. Engsig
Frederik N. Engsig
RZRobert Zangerle
Robert Zangerle
OKOlga Katsarou
Olga Katsarou
FDFrancois Dabis
Francois Dabis
PRPeter Reiss
Peter Reiss
LWLinda Wittkop
Linda Wittkop
Background. Some human immunodeficiency virus (HIV)–infected individuals initiating combination antiretroviral therapy (cART) with low CD4 counts achieve viral suppression but not CD4 cell recovery. We aimed to identify (1) risk factors for failure to achieve CD4 count >200 cells/µL after 3 years of sustained viral suppression and (2) the association of the achieved CD4 count with subsequent mortality. Methods. We included treated HIV-infected adults from 2 large international HIV cohorts, who had viral suppression (≤500 HIV type 1 RNA copies/mL) for >3 years with CD4 count ≤200 cells/µL at start of the suppressed period. Logistic regression was used to identify risk factors for incomplete CD4 recovery (≤200 cells/µL) and Cox regression to identify associations with mortality. Results. Of 5550 eligible individuals, 835 (15%) did not reach a CD4 count >200 cells/µL after 3 years of suppression. Increasing age, lower initial CD4 count, male heterosexual and injection drug use transmission, cART initiation after 1998, and longer time from initiation of cART to start of the virally suppressed period were risk factors for not achieving a CD4 count >200 cells/µL. Individuals with CD4 ≤200 cells/µL after 3 years of viral suppression had substantially increased mortality (adjusted hazard ratio, 2.60; 95% confidence interval, 1.86–3.61) compared with those who achieved CD4 count >200 cells/µL. The increased mortality was seen across different patient groups and for all causes of death. Conclusions. Virally suppressed HIV-positive individuals on cART who do not achieve a CD4 count >200 cells/µL have substantially increased long-term mortality.

15 May 2011 in AIDS
Verified
Journal Article
Closed access
JHJannie J van der Helm
Jannie J van der Helm
MPMaria Prins
Maria Prins
JAJulia del Amo
Julia del Amo
HBHeiner C Bucher
Heiner C Bucher
GCGeneviève Chêne
Geneviève Chêne
RGRonald B Geskus
Ronald B Geskus
Outbreaks of acute hepatitis C virus (HCV) infection among HIV-infected MSM have been described since 2000. However, phylogenetic analysis suggests that the spread of HCV started around 1996. We estimated the incidence of HCV in HIV-infected MSM with well estimated dates of HIV seroconversion from 1990 to 2007. Data from 12 cohorts within the Concerted Action on SeroConversion to AIDS and Death in Europe (CASCADE) Collaboration were used. HCV incidence was estimated using standard incidence methods and methods for interval-censored data. We accounted for the fact that routine HCV data collection in each cohort started in different calendar years. Of 4724 MSM, 3014 had an HCV test result and were included. Of these, 124 (4%) had only positive HCV test results, 2798 (93%) had only negative results and 92 (3%) had both. In 1990, HCV incidence ranged from 0.9 to 2.2 per 1000 person-years, depending on the analysis strategy used. HCV incidence increased up to 1995 when it was estimated to range between 5.5 and 8.1 per 1000 person-years. From 2002 onwards, it increased substantially to values between 16.8 and 30.0 per 1000 person-years in 2005 and between 23.4 and 51.1 per 1000 person-years in 2007. Our data support phylodynamic findings that HCV incidence had already increased among HIV-infected MSM from the mid-1990s. However, the main expansion of the HCV epidemic started after 2002. Incidence estimates obtained from cohort studies may help identify changes in the spread of important infections earlier and should guide routine testing policies to minimize further disease burden.

1 December 1995 in The Journal of Infectious Diseases
Verified
Journal Article
Closed access
PDF file
MDMaria Dorrucci
Maria Dorrucci
PPPatrizio Pezzotti
Patrizio Pezzotti
APAndrew N. Phillips
Andrew N. Phillips
ALAlessandro Cozzi Lepri
Alessandro Cozzi Lepri
GRGiovanni Rezza
Giovanni Rezza
ISItalian Seroeonversion Study
Italian Seroeonversion Study
To assess the influence of hepatitis C virus (HCV) on the natural history of human immunodeficiency virus (HIV) infection, a longitudinal study was conducted among 416 HIV-positive, AIDS-free persons infected through injecting drug use or homosexual or heterosexual activity and with known seroconversion dates. End points were diagnosis of AIDS and a CD4 cell count of < 100 × 106 cells/L. HCV antibodies were detected in 214 persons (51.4%). The crude relative hazard (RH) of progression to AIDS was 0.96 (95% confidence interval [CI], 0.53–1.76) for HCV-coinfected participants compared with those not coinfected. After adjustment for CD4 cell count, the RH was 0.97 (95% CI, 0.52–1.79). Similar RHs were found using a CD4 cell count of <100 × 106 cells/L as the end point. The median CD4 cell loss was 4.83 × 106 cells/L per month among coinfected persons and 5.70 × 106 cellslL per month among the others. These results suggest that coinfection with HCV does not influence clinical and immunologic progression of HIV disease.

15 April 2005 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
GRGiovanni Rezza
Giovanni Rezza
VFValeria Fiorelli
Valeria Fiorelli
MDMaria Dorrucci
Maria Dorrucci
MCMassimo Ciccozzi
Massimo Ciccozzi
ATAntonella Tripiciano
Antonella Tripiciano
Barbara EnsoliBarbara Ensoli
Barbara Ensoli
The human immunodeficiency virus (HIV) type 1 Tat protein plays a key role in the life cycle of the virus and in pathogenesis and is highly conserved